Maven Securities’s Trillium Therapeutics Inc. TRIL Stock Holding History

Maven Securities’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,000	Closed	-$351K	–	1257
2021 Q3	$351K	Buy	+20,000	New	+$234K	0.01%	785
2021 Q2	–	Sell	-285,103	Closed	-$2.98M	–	1501
2021 Q1	$2.98M	Buy	285,103 +135,103	+90%	+$1.67M	0.13%	144
2020 Q4	$2.22M	Buy	+150,000	New	+$2.16M	0.22%	112

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Maven Securities's TRIL Position: Q4 2021 in Review

Maven Securities sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 20,000 shares — an estimated $351K sold.

Maven Securities first reported a position in TRIL in Q4 2020 and held it in 3 quarters. The position peaked at $2.98M in Q1 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Maven Securities reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Maven Securities sold 20,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $351K.
Maven Securities first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 3 quarters.
Maven Securities's Trillium Therapeutics Inc. position peaked at $2.98M in Q1 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Maven Securities's 13F filing for Q4 2021, filed 14 Feb 2022.